Special Issue "Management of Locally Advanced Cervical Cancer"

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Survivorship and Quality of Life".

Deadline for manuscript submissions: 20 December 2023 | Viewed by 997

Special Issue Editors

Department of Radiation Oncology, Amsterdam UMC, University of Amsterdam, Meibergdreef, 1105 AZ Amsterdam, The Netherlands
Interests: radiation oncology
Dr. Constantijne H. Mom
E-Mail Website
Guest Editor
Department of Obstetrics and Gynecology, Center for Gynecological Oncology Amsterdam (CGOA), Amsterdam UMC, Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands
Interests: gynecologic oncology
Dr. Maaike A. Van der Aa
Guest Editor
Department of Research and Development, Netherlands Comprehensive Cancer Organization, 3501 DB Utrecht, The Netherlands
Interests: epidemiology

Special Issue Information

Dear Colleagues,

Cervical cancer is the fourth most common cancer among women. The disease particularly disrupts the lives of women and their families in low- and middle-income countries [1], and in high-income countries women with a barrier to prevention, to early detection and to appropriate care [ref 2]. International efforts against cervical cancer are primarily focused on prevention by vaccination of HPV and screening for pre-malignant stages [3]. The reality is that most preventive strategies will be effective only in the distant future, 20 to 30 years from now, and they do not adequately reach the high-risk population who would benefit most. In underserved populations, the majority of patients present with locally advanced cervical cancer disease (LACC). Therefore, optimal management of women with LACC remains a major and difficult challenge.

In this forthcoming Special Issue, a motivated international team of experts from many medical disciplines will address a comprehensive scope of topics. Topics ranging from a description of the history, epidemiology and demography of patients with LACC, to clinical reviews and original papers on diagnosis, the role of radiotherapy and combined modality treatment, the role of surgery, particularly for nodal disease and for recurrent disease, and the promises of innovative drugs and therapeutic vaccination are all welcome. Considering the major burden of disease and its treatment, the management of late toxicity, and preservation of quality of life will be covered in separate chapters. Since social and economic determinants strongly determine the fate of women with LACC, we will pay special attention to social and economic issues, such as the organization and cost of care for women in low-, middle- and high-income countries.

  1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021:71:209–49. doi:10.3322/caac.21660.
  2. Paper on SES and cervical cancer in Western countries.
  3. WHO—World Health Organization. Cervical Cancer, 22 February 2022.

Prof. Dr. Lukas Stalpers
Dr. Constantijne H. Mom
Dr. Maaike A. Van der Aa
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


17 pages, 2010 KiB  
The Role of Multimodal Imaging in Pathological Response Prediction of Locally Advanced Cervical Cancer Patients Treated by Chemoradiation Therapy Followed by Radical Surgery
Cancers 2023, 15(12), 3071; https://doi.org/10.3390/cancers15123071 - 06 Jun 2023
Viewed by 721
Purpose: This study aimed to develop predictive models for pathological residual disease after neoadjuvant chemoradiation (CRT) in locally advanced cervical cancer (LACC) by integrating parameters derived from transvaginal ultrasound, MRI and PET/CT imaging at different time points and time intervals. Methods: Patients with [...] Read more.
Purpose: This study aimed to develop predictive models for pathological residual disease after neoadjuvant chemoradiation (CRT) in locally advanced cervical cancer (LACC) by integrating parameters derived from transvaginal ultrasound, MRI and PET/CT imaging at different time points and time intervals. Methods: Patients with histologically proven LACC, stage IB2–IVA, were prospectively enrolled. For each patient, the three examinations were performed before, 2 and 5 weeks after treatment (“baseline”, “early” and “final”, respectively). Multivariable logistic regression models to predict complete vs. partial pathological response (pR) were developed and a cost analysis was performed. Results: Between October 2010 and June 2014, 88 patients were included. Complete or partial pR was found in 45.5% and 54.5% of patients, respectively. The two most clinically useful models in pR prediction were (1) using percentage variation of SUVmax retrieved at PET/CT “baseline” and “final” examination, and (2) including high DWI signal intensity (SI) plus, ADC, and SUVmax collected at “final” evaluation (area under the curve (95% Confidence Interval): 0.80 (0.71–0.90) and 0.81 (0.72–0.90), respectively). Conclusion: The percentage variation in SUVmax in the time interval before and after completing neoadjuvant CRT, as well as DWI SI plus ADC and SUVmax obtained after completing neoadjuvant CRT, could be used to predict residual cervical cancer in LACC patients. From a cost point of view, the use of MRI and PET/CT is preferable. Full article
(This article belongs to the Special Issue Management of Locally Advanced Cervical Cancer)
Show Figures

Figure 1

Back to TopTop